ALKERMES | ALKS - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 41.64B 458M 2026-06
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Amgen USD 25.5B 547M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Coherus Biosciences USD 75.51M 56.82M 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
Heron Therapeutics USD 92.14M 1.63M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
J&J USD 54.9B 2.82B 2026-06
Malin Corporation EUR 1000K 500K 2024-12
Merck USD 27.73B 786M 2026-06
Minerva Neurosciences USD 2.29M 381K 2025-12
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Otsuka Holdings JPY 738.96B 52.85B 2026-06
Ovoca Bio EUR 1.3M 1.11M 2025-12
Pfizer USD 32.65B 1.7B 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06